Literature DB >> 11414662

Agmatine and putrescine uptake in the human glioma cell line SK-MG-1.

G J Molderings1, H Bönisch, M Göthert, M Brüss.   

Abstract

The pharmacological properties of a specific agmatine uptake mechanism were investigated in the human glioma cell line SK-MG-1 and compared with those of the putrescine transporter expressed by the same cells and with those of several other organic cation transport systems or ion channels reported in the literature. The specific accumulation of [14C]agmatine at 37 degrees C above nonspecific accumulation at 4 degrees C was energy-dependent and saturable with a Vmax of 64.3+/-3.5 nmol/min per mg protein and a Km of 8.6+/-1.4 microM. Specific accumulation was attenuated by replacement of extracellular Na+ by choline by 65%, not affected by lithium and enhanced by replacement by sucrose. Phentolamine, clonidine, 1,3-di(2-tolyl)guanidine, histamine, putrescine, spermine and spermidine were inhibitors of specific [14C]agmatine accumulation. In contrast, corticosterone, desipramine, O-methylisoprenaline, cirazoline, moxonidine, L-arginine, L-lysine, verapamil, nifedipine and CdCl2 at concentrations up to 10 mM failed to inhibit specific [14C]agmatine accumulation, thus excluding that the latter is mediated by amino acid or monoamine carriers, by Ca2+ channels or by the organic cation transporters OCT1, OCT2, OCT3, OCTN1 or OCTN2. The pattern of activity of inhibitory compounds was also different from that determined for specific putrescine accumulation found in the same cells (Km 1.3+/-0.1 microM, Vmax 26.1+/-0.4 nmol/min per mg protein) ruling out an identity of the specific [14C]agmatine and [14C]putrescine accumulation mechanisms. It is concluded that specific accumulation of agmatine in human glioma cells is mediated by a specific transporter whose pharmacological properties are not identical to those of the agmatine transporter previously identified in rat brain synaptosomes and to other so far known carrier mechanisms for organic cations and ion channels. The agmatine uptake system may be important for the regulation of the extracellular concentration of agmatine in man.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11414662     DOI: 10.1007/s002100100418

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  6 in total

Review 1.  Biological significance of agmatine, an endogenous ligand at imidazoline binding sites.

Authors:  W Raasch; U Schäfer; J Chun; P Dominiak
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

2.  Pharmacological characteristics of the specific transporter for the endogenous cell growth inhibitor agmatine in six tumor cell lines.

Authors:  A Heinen; M Brüss; H Bönisch; M Göthert; G J Molderings
Journal:  Int J Colorectal Dis       Date:  2003-02-20       Impact factor: 2.571

3.  Transport of polyamines in Drosophila S2 cells: kinetics, pharmacology and dependence on the plasma membrane proton gradient.

Authors:  Rafael Romero-Calderón; David E Krantz
Journal:  Biochem J       Date:  2006-01-15       Impact factor: 3.857

4.  OCT2 and MATE1 provide bidirectional agmatine transport.

Authors:  Tate N Winter; William F Elmquist; Carolyn A Fairbanks
Journal:  Mol Pharm       Date:  2010-12-03       Impact factor: 4.939

5.  Agmatine is transported into liver mitochondria by a specific electrophoretic mechanism.

Authors:  Mauro Salvi; Valentina Battaglia; Mario Mancon; Sebastiano Colombatto; Carlo Cravanzola; Rita Calheiros; Maria P M Marques; Maria A Grillo; Antonio Toninello
Journal:  Biochem J       Date:  2006-06-01       Impact factor: 3.857

6.  Agmatine (decarboxylated arginine), a modulator of liver cell homeostasis and proliferation.

Authors:  Bettina Kribben; Jörg Heller; Jonel Trebicka; Tilman Sauerbruch; Michael Brüss; Manfred Göthert; Gerhard J Molderings
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-01-15       Impact factor: 3.000

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.